JP2010215795A5 - - Google Patents

Description

Luminescent substrate for luciferase with controlled wavelength and method for producing the same

  The present invention relates to a method for controlling the emission wavelength of luciferin and luciferin analogs. The present invention also relates to a method for producing a luminescent substrate for luciferase having a controlled wavelength.

Firefly luciferin In recent years, visualization of biological events and phenomena has been emphasized, and the expansion of materials for visualization has been desired. Along with this, diversification is also required in the labeling technology. In particular, labeling techniques for molecular imaging have developed significantly in conjunction with advances in diagnostic and testing equipment. For example, labeling techniques for applying to advanced technologies such as personalized medicine for cancer and heart disease have been energetically studied. In addition, with the advancement of measurement technology, the demand for more sensitive and high-performance instruments and labeling materials is rapidly increasing.

  As is well known, the firefly bioluminescence system is said to have a very high luminous efficiency and to convert energy into light most efficiently. The interpretation of the molecular mechanism of bioluminescence is also progressing.

In this firefly bioluminescence, it is known that luciferin, which is a luminescent substrate, emits light through a chemical reaction by the action of a luminescent enzyme luciferase. In this reaction, the luminescent substrate is adenylylated (AMP) in the presence of adenosine triphosphate (ATP) and divalent magnesium ion (Mg ²⁺ ) in the luminescent enzyme, and the adenylyl derivative is the active substrate. Be guided to. This is then oxygenated to the peroxide anion and converted to a high energy peroxide, dioxetanone. Unstable dioxetanone releases protons and carbon dioxide while decomposing, and enters an excited singlet state. The light emission from this dianion-type excited singlet state is yellowish green, which is considered to be firefly light emission. The product after luminescence is called oxyluciferin.

  As described above, the luminous efficiency is very high, and the molecular mechanism of bioluminescence is elucidated. In addition, the objects for which visualization is desired are expanding, and signs for various materials are desired. Because of these circumstances, a wide variety of luminescent materials using a firefly bioluminescent system are sold by many companies.

  As described above, the luminous efficiency is very high, and the molecular mechanism of bioluminescence is elucidated. Because of these circumstances, a wide variety of luminescent materials using a firefly bioluminescent system are sold by many companies. However, since the development of firefly bioluminescence-related luminescent materials is progressing mainly in the medical biochemical field, research and development from the protein (enzyme) side is generally active, but low molecular weight compounds (substrates) There is very little approach from the side. In particular, there is almost no research on the relationship between structure and activity, such as skeleton transformation of luminescent substrates.

  Furthermore, although a luminescent enzyme can be supplied inexpensively by recombinant technology, a luminescent labeling material using a firefly bioluminescence system such as a kit product is not inexpensive. This is due to the fact that the luminescent substrate is luciferin. At present, D-form luciferin, which is a natural luminescent substrate, is synthesized from D-cysteine, which is an unnatural amino acid, but D-cysteine is very expensive.

Needs and situation of multicolor luminescence using bioluminescence system In order to observe multiple phenomena, multicolor luminescence is also required in detection systems using labels. For this reason, it is desirable that the wavelength range of the labeling material usable for the detection system is wider. Further, for use in deep in vivo labeling, a red light emitting labeling material is desired from the viewpoint that long wavelength light has better light transmittance than short wavelength light. For example, for research using multicolor light emission, it is desirable to prepare a labeling material having light emission over a wavelength of about 450 nm or less to about 650 nm or more as a label.

  Currently available substrates as luminescent substrates for firefly bioluminescent systems include substrates with several emission wavelengths. The shortest and longest end wavelengths of these substrates are coelenterazine blue (about 480 nm) and firefly red (about 613 nm). These are available from Promega and are commercialized. In addition, a longer wavelength red luminescent material (about 630 nm) using a railworm luminescent enzyme is commercially available from Toyobo. However, there is a potential demand for further expansion of not only these emission wavelengths but also the shortest and longest end wavelengths of the emission wavelengths.

Examples of existing red and blue light emitting products using bioluminescent systems are shown below:
1． Promega: Chroma-Luc: approx. 613nm (Non-patent document 1)
This system uses a mutant of clicked beetle (click beetle) and a natural firefly luminescent substrate.
2． Toyobo Co., Ltd .: MultiReporter Assay System-Tripluc: About 630nm (Non-patent document 2)
This system is a system using a railworm red luminescent enzyme and a natural firefly luminescent substrate. The luminescent color is changed using luciferase genes of green luminescence luciferase (SLG, maximum emission wavelength 550 nm), orange luminescence luciferase (SLO, 580 nm) and red luminescence luciferase (SLR, 630 nm). This utilizes luminescent enzymes that give different luminescent colors.
3． The University of Tokyo: Aminoluciferin: About 610nm (Patent Document 1)
This discloses a luciferin derivative.
Four. Promega: Chroma-Luc: Approx. 480nm (Non-patent Document 3)
This system is a system using coelenterazine and Renilla luciferase.
Five. ATTO: Cypridina bioluminescence approximately 460nm (non-patent document 4)
This system uses a coelenterazine-based substrate and Cypridina luciferase.

  The present inventors have also disclosed luciferin-like compounds in Patent Documents 2 and 3. These compounds are compounds having the same skeleton as luciferin.

However, the method for changing the emission wavelength so far has only repeated trial and error by changing the structure at random. Since the bioluminescence system is a chemical reaction in an enzyme, the actual emission wavelength cannot be predicted even by prediction based on modern energy calculation or theoretical structural analysis. Therefore, it is desired to develop a systematic conversion index for predicting the emission wavelength of a luminescent substrate for a firefly bioluminescence system. It is also desired to develop a method for producing a luminescent substrate having a desired wavelength.
Japanese Unexamined Patent Publication No. 2007-091695 International Publication No. 2007/116687 Pamphlet JP 2006-219381 A Promega General Catalog 2008-9 12.6 Upload vol. 79, 2005 p 1-10, Toyobo Biochemicals for Lifescience 2006/2007 p4-67. Promega General Catalog 2008-9 12.14 Ato General Catalog 2008-2009 p 247

  In view of the above situation, an object of the present invention is to provide a method for producing a substrate having a desired emission wavelength different from that of a natural firefly luminescence substrate in a firefly bioluminescence system. Another object of the present invention is to provide a group of substrates having a broad emission wavelength of a firefly bioluminescence system.

  In order to achieve the above object, the present inventors made a group of analogs of a luminescent substrate having a similar structure, and analyzed the emission wavelength. As a result, in the structure of the luciferin analog, every time a double bond is extended, the emission wavelength is shifted by about 100 nm to the longer wavelength side, and the double bond portion is converted into a benzene ring, thereby generating an emission wavelength. Has been found to shift about 20-30 nm to the longer wavelength side, and to change the emission wavelength to about 20-30 nm to the shorter wavelength side by changing the dialkylamino group to a hydroxyl group. As a result, an index for changing a practical emission wavelength could be established.

  As described above, the structure-activity relationship in many analogs of luciferin, which is the luminescent substrate in the firefly bioluminescence system, reveals the essential sites for luminescence and the sites that affect luminescence in luciferin and its analogs. did it. These findings have led to the completion of the present invention.

The present invention relates to a method for producing a substrate of luciferase having a desired emission wavelength, and in order to shift the emission wavelength, an —OH group or an —NR ₁ R ₂ group (wherein R ₁ And R ₂ are each independently H or C _1-4 alkyl) in order to produce a compound in which one is substituted with the other and / or to shift the emission wavelength in luciferin or luciferin analogs Producing a compound in which the number of double bonds is increased or decreased and / or producing a compound in which one of the double bond moiety or the benzene ring is substituted with the other in order to shift the emission wavelength. Provide a method.

式中、R₁、R₂およびR₃は、それぞれ独立してHまたはC_1-4アルキルであり、XおよびYは、それぞれ独立してC、N、SまたはOであり、nは、2である。 The present invention also provides luciferin analogs of general formula III:

Wherein R ₁ , R ₂ and R ₃ are each independently H or C _1-4 alkyl, X and Y are each independently C, N, S or O, and n is 2 It is.

The present invention also provides the above compound, wherein R ₁ R ₂ N— group is —OH group and R ₃ is H.

Furthermore, the present invention provides a luminescent substrate comprising the luciferin analog described above .

The present invention also provides a luminescence detection kit comprising the luciferin analog described above .

According to the present invention, luciferin analogs are provided.

The figure which shows the light emission wavelength of the luciferin analog group of this invention. The figure which shows the structure which converts the light emission wavelength and light emission wavelength of the luciferin analog group of this invention.

The present invention relates to a method for producing a substrate of luciferase having a desired emission wavelength, and in order to shift the emission wavelength, an —OH group or an —NR ₁ R ₂ group (wherein R ₁ And R ₂ are each independently H or C _1-4 alkyl) in order to produce a compound in which one is substituted with the other and / or to shift the emission wavelength in luciferin or luciferin analogs Producing a compound in which the number of double bonds is increased or decreased, and / or producing a compound in which one of the double bond moiety or the benzene ring is substituted with the other in order to shift the emission wavelength. A method of including is provided.

の構造を有するホタルルシフェリンである。 As used herein, luciferin refers to the following formula I:

Firefly luciferin having the structure

  In the present specification, the luciferin derivative includes a non-natural compound capable of emitting light through a chemical reaction through the action of the luminescent enzyme luciferase. Luciferin derivatives include compounds having a different skeleton from naturally occurring luciferins.

の構造を有する。 Luciferin derivatives include, for example, the following general formula II:

It has the following structure.

In the above general formula II, R ₁ , R ₂ and R ₃ can each independently be H or C _1-4 alkyl. Such lower alkyls as substituents are considered unlikely to affect activity. In a preferred embodiment, R ₁ and R ₂ are methyl. In a preferred embodiment, R ₃ is H. In the general formula II, the —NR ₁ R ₂ group can be an —OH group.

As used herein, the term “C _1-4 alkyl” refers to a saturated linear or branched alkyl group containing from 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl. , Iso-butyl, sec-butyl and tert-butyl. Similarly, the term “C ₁ -C ₃ alkyl” refers to a saturated linear or branched alkyl group containing from 1 to 3 carbon atoms (eg, methyl, ethyl or iso-propyl).

As noted above, one skilled in the art can readily appreciate that R ₃ may be C _1-4 alkyl. For example, the above-mentioned Patent Document 2 by the present inventors shows that a luciferin-like compound in which the portion corresponding to the R ₃ portion of the compound of the present invention is AMP can serve as a substrate for a firefly bioluminescence system.

  In the above general formula II, X and Y can each independently be C, N, S or O. One skilled in the art will readily realize that the heteroatoms of X and Y may be C, N, S or O. For example, the various luciferin-like compounds described in the above-mentioned Patent Document 2 by the present inventors include luciferin-like compounds in which the corresponding parts of the compound of the present invention are various heteroatoms as a substrate for a firefly bioluminescence system. The results obtained are shown.

  In the general formula II, the double bond unit (vinylene unit) represented as “n” can be changed to a desired length. In preferred embodiments, n is 0, 1, 2 or 3.

の構造を有する。 Further, luciferin derivatives include, for example, the following general formula III:

It has the following structure.

In the above general formula III, R ₁ , R ₂ and R ₃ can each independently be H or C _1-4 alkyl. Such lower alkyls as substituents are considered unlikely to affect activity. In a preferred embodiment, R ₁ and R ₂ are methyl. In a preferred embodiment, R ₃ is H. In the general formula III, the —NR ₁ R ₂ group can be an —OH group.

As noted above, one skilled in the art can readily appreciate that R ₃ may be C _1-4 alkyl. For example, the above-mentioned Patent Document 2 by the present inventors shows that a luciferin-like compound in which the portion corresponding to the R ₃ portion of the compound of the present invention is AMP can serve as a substrate for a firefly bioluminescence system.

  In the above general formula III, X and Y can each independently be C, N, S or O. One skilled in the art will readily realize that the heteroatoms of X and Y may be C, N, S or O. For example, the various luciferin-like compounds described in the above-mentioned Patent Document 2 by the present inventors include luciferin-like compounds in which the corresponding parts of the compound of the present invention are various heteroatoms as a substrate for a firefly bioluminescence system. The results obtained are shown.

  In the above general formula III, the double bond unit (vinylene unit) represented as “n” can be changed to a desired length. In preferred embodiments, n is 0, 1, 2 or 3.

  In the present invention, luciferin and luciferin analogs include salts thereof. A “salt” is envisioned only in the compounds of the present invention where any portion of the compound can form a base.

  The expression "salt" includes hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, phosphorous acid, nitrous acid, citric acid, formic acid, acetic acid, oxalic acid, maleic acid, lactic acid , Tartaric acid, fumaric acid, benzoic acid, mandelic acid, cinnamic acid, pamoic acid, stearic acid, glutamic acid, aspartic acid, methanesulfonic acid, ethanedisulfonic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, trifluoroacetic acid and Any salt with an inorganic or organic acid that is non-toxic to living organisms, or where the nature of the compound of formula I is acidic, an alkali or alkaline earth base such as hydroxylated Also included are salts with inorganic bases such as sodium, potassium hydroxide, calcium hydroxide and the like.

The method for producing a luciferase substrate having a desired emission wavelength according to the present invention produces a compound in which —OH group and —NR ₁ R ₂ group in luciferin or a luciferin analog are substituted in order to shift the emission wavelength. Process. “One of the —OH group or —NR ₁ R ₂ group is substituted with the other” means that in the case of a compound having an —OH group, the —OH group is substituted with the —NR ₁ R ₂ group, and — In the case of a compound having an NR ₁ R ₂ group, this means that the —NR ₁ R ₂ group is substituted with an —OH group.

By changing the —OH group in the luciferin or luciferin analog to the —NR ₁ R ₂ group, the emission wavelength can be shifted to the long wavelength side by about 20 to 30 nm or more. Conversely, by changing the —NR ₁ R ₂ group in the luciferin or luciferin analog to the —OH group, the emission wavelength can be shifted to the short wavelength side by about 20 to 30 nm or more.

For example, when it is desired to shift the emission wavelength of luciferin of formula I to the longer wavelength side, a derivative in which the —OH group of luciferin is substituted with —NMe ₂ group can be produced. Also, the following formula IV:

のルシフェリン誘導体の発光波長を短波長側にシフトさせたいときは、ルシフェリン誘導体の-NMe₂基が-OH基に置換された式V：

When the emission wavelength of the luciferin derivative is to be shifted to the short wavelength side, the formula V in which the —NMe ₂ group of the luciferin derivative is replaced with the —OH group:

の誘導体を製造することができる。この場合、発光波長は、式IVのルシフェリン誘導体の約450nmから約430nmにシフトされる。

Can be produced. In this case, the emission wavelength is shifted from about 450 nm to about 430 nm of the luciferin derivative of formula IV.

Compounds in which _one of the —OH group or —NR ₁ R ₂ group in luciferin or a luciferin analog is replaced with the other can be prepared using various methods well known to those skilled in the art. For example, it can be synthesized by a synthetic route as shown in the following examples.

  The production method of the present invention includes a step of producing a compound in which the number of double bonds in luciferin or a luciferin analog is increased or decreased in order to shift the emission wavelength. “Increasing the number of double bonds” refers to adding / inserting a double bond, that is, adding / inserting a vinylene unit in a carbon bond of luciferin or a luciferin analog. For example, in the compounds of general formulas II and III, this means increasing the number of n. “Reducing the number of double bonds” means removing double bonds, ie, removing vinylene units, at the carbon bond of luciferin or a luciferin analog. For example, in the compounds of general formulas II and III, it means to reduce the number of n. The number of double bonds in the luciferin analog, i.e. n, can be increased or decreased depending on the desired emission wavelength, but is preferably between 0 and 3.

  By increasing the number of double bonds in the carbon bond of luciferin or luciferin analog, the emission wavelength can be shifted to the long wavelength side by about 100 nm or more. Conversely, by reducing the number of double bonds in the carbon bond of luciferin or a luciferin analog, the emission wavelength can be shifted to the short wavelength side by about 100 nm or more.

  For example, when the emission wavelength of the luciferin derivative of formula IV is desired to be shifted to the longer wavelength side, formula VI in which vinylene is added to the 3-position of the N, N-dialkylaniline moiety of the compound:

の誘導体を製造することができる。この場合、発光波長は、式IVのルシフェリン誘導体の約450nmから約560nmにシフトされる。

Can be produced. In this case, the emission wavelength is shifted from about 450 nm to about 560 nm of the luciferin derivative of formula IV.

  Compounds with increased or decreased number of double bonds in luciferin or luciferin analogs can be prepared using various methods well known to those skilled in the art. For example, it can be synthesized by a synthetic route as shown in the following examples.

  The production method of the present invention includes a step of producing a compound in which a double bond portion and a benzene ring in luciferin or a luciferin analog are substituted in order to shift the emission wavelength. By substituting the double bond moiety in luciferin or luciferin analog with a benzene ring, the emission wavelength can be shifted to the long wavelength side by about 20 to 30 nm or more. Conversely, by replacing the benzene ring moiety in luciferin or a luciferin analog with a conjugated double bond, the emission wavelength can be shifted to the short wavelength side by about 20-30 nm or more.

  A compound in which “one of the double bond moiety or the benzene ring is substituted with the other” means that the double bond in the carbon bond of the luciferin or luciferin analog forms a condensed ring together with the adjacent benzene ring. A compound in which a ring is substituted, or vice versa, a compound in which a benzene ring forming a condensed ring with an adjacent benzene ring is substituted with a double bond. For example, Formula VII:

の誘導体のように、フェノールのベンゼン環にビニレンが1つ結合している誘導体の場合、ビニレン部分がベンゼン環に置換されることにより、式VIII：

In the case of a derivative in which one vinylene is bonded to the benzene ring of phenol, such as the derivative of ## STR4 ##

の誘導体のように、ナフタレン環を含む誘導体を形成させる。また、上記式VIIIの誘導体のように、ナフトールのベンゼン環にビニレンが1つ結合している誘導体の場合、ビニレン部分がベンゼン環に置換されることにより、アントラセン環を含む誘導体を形成させる。

A derivative containing a naphthalene ring is formed. Further, in the case of a derivative in which one vinylene is bonded to the benzene ring of naphthol, such as the derivative of the above formula VIII, a derivative containing an anthracene ring is formed by substituting the vinylene moiety with a benzene ring.

  The number of benzene rings in the condensed ring can be increased or decreased depending on the desired emission wavelength, but is preferably 0 to 3, more preferably 0 to 2.

  Compounds in which the double bond moiety and benzene ring in luciferin or luciferin analog are substituted can be prepared using various methods well known to those skilled in the art. For example, it can be synthesized by a synthetic route as shown in the following examples.

The present invention also provides a luciferase derivative obtained by the above method for producing a luciferase substrate. For example, the compounds encompassed by the general formulas II and III can be produced by the production method of the present invention. In addition, a compound in which the —NR ₁ R ₂ groups of the general formulas II and III are —OH groups can be produced by the production method of the present invention. A compound in which the —NR ₁ R ₂ group of the luciferin derivative is an —OH group can be produced using various methods well known to those skilled in the art. For example, it can be synthesized by a synthetic route as shown in the following examples.

The compounds of the present invention can be made, for example, according to the procedures described in Example 7 below. More detailed procedures are described in the examples below. Example 7 describes a synthesis procedure of a dimethylaniline type compound in which R ₁ and R ₂ of the general formula II are each methyl, R ₃ is H, and n is 2. Briefly, an aldehyde form such as commercially available 4-dimethylaminocinnamic aldehyde is used as a starting material, and reacted with carbethoxymethylenetriphenylphosphorane to obtain an ethyl ester form. Subsequently, this ethyl ester body is converted into a carboxyl body in an aqueous sodium hydroxide solution. On the other hand, a D-cysteine-S-trityl compound is reacted in hydrogen chloride and 1,4-dioxane solution to prepare a methyl ester form. Next, this methyl ester form is reacted with a carboxyl form to form an amide form. Next, this amide form is cyclized with triphenylphosphine oxide and trifluoromethanesulfonic anhydride to form a heterocyclic ring to obtain a thiazoline form. Next, the methyl ester portion of the thiazoline is converted to a desired substituent to obtain the desired compound.

A person skilled in the art will react with a methyl ester derivative derived from D-cysteine-S-trityl by the same procedure as in Example 1, starting from a starting material in which R ₁ and R ₂ are replaced with the desired substituents. It will be understood that the corresponding compounds can be synthesized. In the last step, the methyl ester moiety of the thiazoline body is substituted with a desired ester, so that a compound having the corresponding R ₃ can be obtained. Furthermore, by changing the length of the olefin part of the ethyl ester form used as the starting material, it will be possible to obtain a compound having the desired length n in the general formula II.

The compounds of the invention can also be made, for example, according to the procedures described in Example 3 below. Example 3 describes a synthetic procedure for a compound in which the —NR ₁ R ₂ group of general formula III is an —OH group, R ₃ is H, and n is 1. More detailed procedures are described in the examples below. One skilled in the art would be able to synthesize the desired compound using synthetic procedures similar to those described in the examples below.

The compound produced by the production method of the present invention is oxidized by the luminescent beetle luciferase when added to a system containing luminescent beetle luciferase, ATP and Mg ²⁺ to emit light. Such a compound can be used alone as a luminescent substrate, but may be used in combination with other luminescent substrates as necessary. Such compounds can also be provided as a kit with ATP and Mg ²⁺ . The kit can also contain other luminescent substrates and solutions prepared at an appropriate pH. Further, such a compound can be provided as a kit with a luminescent substrate composition prepared by adjusting the compound of the present invention to an appropriate pH together with ATP and Mg ²⁺ . In addition, the compound produced by the production method of the present invention can be used as various luminescent agents. Moreover, the compound manufactured by the manufacturing method of this invention can be utilized as a sensor.

  For example, since the firefly bioluminescence system is an aqueous system, a hydrophilic organic compound may be present. For example, tetrafluoroacetic acid, acetic acid, formic acid and the like may be present. When the compound of the present invention is applied to a luminescent system, it is preferably used at a concentration of a luminescent substrate of 1 μM or more, for example, 5 μM or more in order to obtain a suitable luminescence intensity. The pH of the light emitting system is assumed to be 4 to 10, preferably 6 to 8, but is not particularly limited. If necessary, buffering agents such as potassium phosphate, Tris-HCl, glycine and HEPES can be used to stabilize the pH.

  In addition, the compound of the present invention can be made to emit light by various oxidases in the luminescent beetle luciferase luminescence system. Luciferase has been isolated from various organisms such as North American firefly (Photinus pyralis) and Railroad worm, any of which can be used. Oxidases that can be used include, for example, light beetle luciferase, Iriomote luciferase and flavin-containing monooxygenase.

It is known that bioluminescence using the compound of the present invention as a luminescent substrate is enhanced in the presence of coenzyme A (CoA), pyrophosphate or Mg ion (Mg ²⁺ ) in the luminescent system. Therefore, these can be used as a luminescence enhancer of the luminescent beetle luciferase luminescence system. It is known that the luminescence enhancement effect of these compounds is remarkable when the concentration of CoA, pyrophosphate or Mg ²⁺ in the luminescence system is 5 μM or more, respectively, and is enhanced as the concentration increases.

  In order to use the firefly bioluminescence system for measurement / detection, it is important to stabilize the luminescence so as to prevent inactivation of the enzyme and exhibit a plateau luminescence behavior. For example, Mg ions are effective for stabilizing luminescence in a firefly bioluminescence system. When Mg ions are present in the light-emitting system, the light-emission behavior changes so that attenuation after rising is suppressed. In particular, when pyrophosphate and Mg ions coexist in the luminescent system, the luminescence behavior changes greatly. That is, the stabilization of luminescence becomes extremely remarkable, and the luminescence behavior when a large excess of pyrophosphate and Mg ions coexist with the luminescent substrate rises rapidly and is maintained to form a plateau state. In the case of Mg ion alone, when the Mg ion concentration of the light emitting system is 0.5 mM or more, the light emission stabilizing effect is remarkable, and is enhanced as the Mg ion concentration increases. In order to achieve a plateau emission behavior, magnesium pyrophosphate can be present, for example, at a concentration of 10 μM or more, preferably 100 μM or more. Moreover, the ratio of pyrophosphoric acid and Mg ion does not need to be an equivalent ratio. Although magnesium pyrophosphate has low water solubility, it can be used to supply pyrophosphate and Mg ions separately. These can be supplied to the luminescent system in free form and in salt form. Mg salts that can be used include inorganic acid salts such as magnesium sulfate and magnesium chloride, and organic acid salts such as magnesium acetate. Pyrophosphates include salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as magnesium and calcium, salts with iron and the like. These may be included in the light emitting system in an aqueous solution state. In consideration of the effect on the enzyme, the pH of the luminescent system is preferably 2-10.

  The compounds of the present invention may be used as substrates in chemiluminescence. Chemiluminescence occurs when the compound of the present invention is oxidized to produce a peroxide, and the decomposition product of the peroxide becomes a luminescent species in an excited state. Oxidation can proceed by air oxidation using, for example, potassium t-butoxy in DMSO. In the case of chemiluminescence, luminescence with a shorter wavelength than that in the firefly bioluminescence system is assumed.

  The compounds of the present invention can be used as luminescent labels in biological measurements / detections. For example, it can be used to label amino acids, polypeptides, proteins, nucleic acids and the like. Means for conjugating the compounds of the present invention to these materials are well known to those of skill in the art. For example, the compounds of the present invention can be coupled to the carboxyl and amino groups of the target substance using methods well known to those skilled in the art.

  In addition, the compound of the present invention can be used for measurement / detection utilizing detection of luminescent beetle luciferase activity by luminescence of a luminescent substrate. For example, a compound of the present invention is reacted under conditions suitable for reaction with a luminescent beetle luciferase as described above. The luminescence from the compound is then detected. For example, by administering the compound of the present invention to a cell or animal into which a luciferase gene has been introduced, the expression of a target gene or protein in vivo can be measured / detected. The compounds of the present invention can emit light at different emission wavelengths. Therefore, by using a plurality of compounds, luminescence from a plurality of targets can be measured / detected simultaneously. In addition, since the longer the wavelength, the more transparent the tissue, the higher the tissue permeability. Therefore, among the compounds of the present invention, compounds having long-wavelength light emission are useful for in vivo deep labeling.

  The compound produced by the production method of the present invention realizes light emission in a wide range of emission wavelengths. With these series of analog substrates, RGB light emission, which is the three primary colors of light, can be realized with firefly luciferin analogs. In addition, the blue wavelength shorter than 450 nm and the red wavelength longer than 650 nm, which correspond to both ends, are emission wavelength regions that could not be achieved by existing firefly bioluminescence systems.

  As described above, light emission by the compound produced by the production method of the present invention can correspond to RGB which is the three primary colors of light. It is well known that any color tone can be obtained by combining the three primary colors of light. Therefore, by combining compounds with emission wavelengths corresponding to the three primary colors, light emission of infinite color tone can be obtained. In addition, when compounds with emission wavelengths corresponding to the three primary colors are used for measurement / detection utilizing the detection of luminescent beetle luciferase activity by the emission of the luminescent substrate, as a result, depending on the degree of emission of each of the three primary colors Light emission of different colors will be obtained. Therefore, it will be possible to simultaneously determine the degree of light emission of each of the three primary colors from the obtained light emission color tone. It would also be possible to select and measure and detect the desired wavelength using a filter or the like.

  A luminescent substrate that emits light at a shorter wavelength (about 500 nm or less) than firefly luciferin can transfer energy to the green fluorescent protein (GFP) of the luminescent jellyfish. By such energy transfer, fluorescence (about 520 nm) is emitted from the green GFP. By using this luminescent substrate, a BRET (Bioluminescence Resonance Energy Transfer) type luminescent system using a GFP / luminescent beetle luciferase fusion protein can be constructed. The BRET-type luminescence system allows bioimaging of various protein post-translational modifications and gene expression. For example, when GFP and a luminescent beetle luciferase fusion protein are expressed via a protein processing sequence, green fluorescence of GFP is detected if the fusion protein is not processed. Conversely, when the fusion protein is processed, blue emission of the luminescent substrate is detected. Therefore, bioimaging about the expression of the enzyme that processes the fusion protein is possible based on the luminescent state. In addition, measurement of protein amount and bioimaging of protein localization can be performed. Furthermore, it can also be used for bioimages of sugar chain addition processes necessary for protein ripening. It can also be used to observe protein / protein interactions.

  In the following examples, the present invention is specifically described, but the present invention is not limited to these ranges.

1) Instrument analysis and measurement equipment
pH measurement: Measured using pH test paper UNIV manufactured by Toyo Roshi Kaisha, Ltd. Moreover, it measured using pH / ION METER F-23 by Horiba as a pH meter.

  Melting point measurement (m.p.): Measured using model MP-2 manufactured by Yamamoto. The measured value is uncorrected.

Infrared absorption spectrum (IR): Measured by tablet method (KBr) and solution method (CHCl ₃ , CH ₃ OH) using FT-730 Fourier transform infrared spectrophotometer manufactured by HORIBA, Ltd. The measured value was described in wave number (cm ⁻¹ ). In addition, wide absorption was described as br.

¹ H nuclear magnetic resonance spectrum ( ¹ H NMR): Measured using a Lambda-270 type apparatus (270 MHz) manufactured by JEOL Ltd. It was described as “ ¹ H NMR (measurement frequency, measurement solvent): δ chemical shift value (number of hydrogen, multiplicity, spin coupling constant)”. The chemical shift value (δ) is expressed in pp using tetramethylsilane (δ = 0) as an internal standard. Multiplicity is displayed as s (single line), d (double line), t (triple line), q (quadruple line), m (multiple line or complex overlapping signals) It was written. The spin coupling constant (J) is described in Hz.

¹³ C nuclear magnetic resonance spectrum ( ¹³ C NMR): Measured using a Lambda-270 type apparatus (67.8 MHz) manufactured by JEOL Ltd. “ ¹³ C NMR (measurement frequency, measurement solvent): δ chemical shift value (multiplicity)” is described. The chemical shift value (δ) is expressed in ppm with tetramethylsilane (δ = 0) as an internal standard. The multiplicity is indicated by s (single line), d (double line), t (triple line), and q (quadruple line).

  Mass spectrum (MS): Measured by electron impact method (EI, ionization energy: 70 eV) using a JMS-600H mass spectrometer manufactured by JEOL Ltd. It measured by the electron spray ionization method (ESI) using the JEOL company JMS-T100LC type TOF mass spectrometer AccuTOF. The apparatus was set to a solvent removal gas of 250 ° C., an orifice 1 temperature of 80 ° C., a needle voltage of 2000 V, a ring lens voltage of 10 V, an orifice 1 voltage of 85 V, and an orifice 2 voltage of 5 V. Sample feeding was performed by the infusion method, and the flow rate was 10 μl / min. It was described as “MS (measurement method) m / z mass number (relative intensity)”.

Specific rotation: measured using a DIP-1000 polarimeter manufactured by JASCO Corporation. A sodium lamp was used as the light source, and a cylindrical glass cell (Φ10 × 100 mm) was used as the cell. The measured values are uncorrected, and the data is the average of 5 measurements. For each of D-form and L-form, “D or L: [α] ^temperature measurement value (concentration, measurement solvent)” was described.

2) Chromatography Analytical thin layer chromatography (TLC):. E Merck Co. TLC plates, using silica gel 60F ₂₅₄ (Art.5715) thickness 0.25 mm. The detection of the compound on TLC was carried out by UV irradiation (254 nm or 365 nm) and immersion in a color former, followed by heating to cause color development. As the color former, p-anisaldehyde (9.3 ml) and acetic acid (3.8 ml) dissolved in ethanol (340 ml) and concentrated sulfuric acid (12.5 ml) were added.

Preparative thin layer chromatography (PTLC): E. Merck TLC plate, silica gel 60F ₂₅₄ (Art.5744) 0.5 mm thick, or E. Merck silica gel 60GF for thin layer chromatography ₂₅₄ (Art. 7730) was prepared on a 20 cm × 20 cm glass plate adjusted to a thickness of 1.75 mm.

Silica gel column chromatography: silica gel 60F ₂₅₄ (Art. 7734) manufactured by E. Merck was used.

3) Basic operation The reaction solution was cooled by immersing the reaction vessel in a dewar filled with refrigerant. Ice water was used at room temperature to 4 ° C, and liquid nitrogen-acetone was used as a refrigerant at 4 to -90 ° C. The extracted solution after the reaction was dried by washing with saturated brine and then adding anhydrous sodium sulfate or anhydrous magnesium sulfate. About what performed neutralization with the resin after reaction, the cation exchange resin Amberlite IR120B NA or the anion exchange resin Amberlite IRA400 OH AG made by Organo Corporation was used. The solution was concentrated under reduced pressure using a rotary evaporator under reduced pressure of an aspirator (20 to 30 mmHg). The trace amount of solvent was removed using a vacuum pump (about 1 mmHg) equipped with a trap cooled in a liquid nitrogen bath. All solvent mixing ratios were expressed in volume ratios.

4) Solvent Distilled water was distilled and ion-exchanged using a GS-200 type distilled water production apparatus manufactured by Advantech Toyo Corporation.

  Toluene, methanol, ethanol, isopropanol, dichloromethane, tetrahydrofuran, N, N-dimethylformamide, 2-butanone, dehydrated solvent for organic synthesis or special grade solvent manufactured by Kanto Chemical Co., Ltd., using molecular sieves (4A) Used.

The solvent for NMR measurement used the following as it was. CDCl ₃ : 99.7 ATOM% D, 0.03% TMS made by ISOTEC Inc., CD ₃ OD: 99.8 ATOM% D (˜0.7 ATOM% ¹³ C) made by ISOTEC Inc., 0.05% TMS.

Example 1: Synthesis of a dimethylaniline-type luminescent substrate

  4-Dimethylaminobenzonitrile (103 mg, 0.706 mmol) and D-cysteine hydrochloride monohydrate (371 mg, 2.12 mmol) are dissolved in ethanol (4 ml), and 1M aqueous sodium hydroxide solution (5 ml) is added under an argon atmosphere. The mixture was further stirred at 80 ° C. for 5 hours. The reaction mixture was acidified with 1M hydrochloric acid (5 ml) and concentrated under reduced pressure. The resulting solid was filtered and washed with distilled water to give the analog (50.9 mg, quant.) As a yellow solid.

Dimethylaniline-type luminescent substrate
¹ H NMR (270 MHz, CDCl ₃ )
δ3.01 (6H, s), 3.50 (1H, dd, J = 9.2, 11Hz), 3.61 (1H, dd, J = 9.2, 11Hz), 5.00 (1H, t, J = 9.2Hz), 6.71 (2H , dd, J = 2.4, 7.0 Hz), 7.71 (2H, dd, J = 2.4, 7.0 Hz).

Example 2: OH-Naphthalene Type Synthesis of Naphthalene Analog 1

6-シアノ-2-ナフトール（49.6mg, 0.292mmol）、D-システイン塩酸塩一水和物（140.5mg, 0.797mmol）をアルゴン雰囲気下、脱水エタノール（5.0mL）と1M水酸化ナトリウム水溶液（2.5mL）の混合溶液に溶解させ、80℃で4時間加熱攪拌した。反応混合物を放冷後、1M塩酸（2mL）を加え、蒸留水で洗浄し、類似体1（43.4mg, 54%）を黄色固体として得た。

6-Cyano-2-naphthol (49.6 mg, 0.292 mmol), D-cysteine hydrochloride monohydrate (140.5 mg, 0.797 mmol) in an argon atmosphere with dehydrated ethanol (5.0 mL) and 1M aqueous sodium hydroxide (2.5 mL) and was stirred with heating at 80 ° C. for 4 hours. The reaction mixture was allowed to cool, 1M hydrochloric acid (2 mL) was added, and the mixture was washed with distilled water to give analog 1 (43.4 mg, 54%) as a yellow solid.

Analog 1
¹ H NMR (270 MHz, CD ₃ OD)
δ 3.73 (2H, dd, J = 3.9, 8.9Hz), 5.33 (1H, t, J = 8.9Hz), 7.20-8.20 (6H, complex).

Example 3: OH-naphthalene-monoene type
Synthesis of TBS protector 2

  6-Cyano-2-naphthol (50.2 mg, 0.297 mmol), t-butyldimethylsilyl chloride (143 mg, 0.95 mmol) and imidazole (160.7 mg, 2.37 mmol) are dissolved in DMF (0.5 mL) and allowed to stand at room temperature for 1 hour. Stir. Water (40 mL) was added to the reaction mixture and extracted with ethyl acetate (3 × 60 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography {silica gel 36 g; hexane-ethyl acetate (8: 1)} to obtain TBS protector 2 (69.9 mg, 83%) as a colorless oil.

Analog 2
¹ H NMR (270 MHz, CDCl ₃ )
δ 0.01 (6H, s), 0.74 (9H, s), 6.80 to 7.80 (6H, complex).

Synthesis of aldehyde 3

  TBS protector 2 (99.3 mg, 0.35 mmol) and 0.5 mL of 1M diisobutylaluminum (toluene solution) were dissolved in dehydrated toluene (10 mL) under an argon atmosphere and stirred for 1 hour. The reaction mixture was ice-cooled, acetone (10 mL), saturated aqueous Rochelle salt solution (20 mL), water (30 mL) were added, and the mixture was extracted with ethyl acetate (3 × 50 mL). The organic layer was dried by adding sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 1 sheet; hexane-ethyl acetate (10: 1)} to give aldehyde 3 (74.4 mg, 74%) as a yellow oil Got as.

Aldehyde body 3
¹ H NMR (270 MHz, CDCl ₃ )
δ 0.28 (6H, s), 1.03 (9H, s), 7.00 to 7.80 (6H, complex), 10.10 (1H, s).

Synthesis of ester 4

  Aldehyde compound 3 (63.9 mg, 0.22 mmol) and carbethoxymethylenetriphenylphosphorane (121 mg, 0.349 mmol) were dissolved in toluene (2 mL), and the mixture was stirred at room temperature for 5 hours. Water (50 mL) was added to the reaction mixture and extracted with ethyl acetate (3 × 50 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 1 sheet; hexane-ethyl acetate (25: 1)} to give ester 4 (76.6 mg, 97%) as a yellow oil Obtained.

Ester 4
¹ H NMR (270 MHz, CDCl ₃ )
δ 0.25 (6H, s), 1.00 (9H, s), 1.43 (3H, t, J = 7.0Hz), 4.23 (2H, q, J = 7.1Hz), 5.95 (1H, d, J = 12.5Hz) 6.47 (1H, d, J = 16.1 Hz), 7.01-7.80 (7H, complex).

Synthesis of carboxylic acid 5

  Ester 4 (90.8 mg, 0.253 mmol) was dissolved in isopropyl alcohol (3 mL), 1M aqueous sodium hydroxide solution (5 mL) was added, and the mixture was stirred for 5 hr. The reaction mixture was neutralized by adding cation exchange resin IR-120BNa. The resin was filtered off and the filtrate was concentrated under reduced pressure to give carboxylic acid 5 (54.9 mg, quant.) As a pale yellow solid.

Carboxylic acid 5
¹ H NMR (270 MHz, CD ₃ OD)
δ 6.47 (1H, d, J = 15.8 Hz), 7.00-7.90 (7H, complex).

Synthesis of methyl ester 6

  D-cysteine-S-trityl compound (504 mg, 1.39 mmol) was dissolved in methanol (100 ml), and 4N hydrogen chloride in 1,4-dioxane (5.4 ml) was added. After stirring at room temperature for 17 days, neutralization was performed using an anion exchange resin IRA400 OH AG. The resin was filtered off and the resulting solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography {silica gel 33.6 g; hexane-ethyl acetate (1: 1)} to obtain methyl ester 6 (455 mg, 86%) as a pale yellow oil.

Methyl ester 6
IR (neat) 3380, 3320, 1740, 1600cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ2.47 (1H, dd, J = 8.1, 13Hz), 2.60 (1H, dd, J = 5.1, 13Hz), 3.21 (1H, dd, J = 5.1, 8.1Hz), 3.66 (3H, s), 7.18 -7.32 (9H, complex), 7.40-7.54 (6H, complex)
¹³ C NMR (67.8MHz, CD ₃ OD)
δ36.90 (t), 52.16 (q), 53.78 (d), 66.83 (s), 126.8 (d) x 3, 127.9 (d) x 6, 129.6 (d) x 6, 144.5 (s) x 3, 174.2 (s).

Synthesis of amide 7

  Carboxylic acid 5 (54.9 mg, 0.254 mmol), 1-ethyl-3- (3-dimethylaminopropyl) hydrochloride in an N, N-dimethylformamide solution (1 ml) in methyl ester 6 (145 mg, 0.381 mmol) under an argon atmosphere Carbodiimide (145 mg, 0.762 mmol) and 4-dimethylaminopyridine (155 mg, 1.27 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 2 sheets; hexane-ethyl acetate (2: 1)} to give amide compound 7 (58.4 mg, 40%) as pale yellow Obtained as an oil.

Amide body 7
¹ H NMR (270 MHz, CDCl ₃ )
δ 2.75 (2H, dd, J = 4.6, 7.9Hz), δ3.75 (3H, s), 4.77 (1H, dd, 2.7, 7.9Hz), 6.35 (1H, d, J = 16.1Hz), 6.90 ~ 7.80 (22H, complex).

Synthesis of thiazoline 8

  Triphenylphosphine oxide (91 mg, 0.327 mmol) and trifluoromethanesulfonic anhydride (100 μL, 0.546 mmol) were added to a solution of amide 7 (60.3 mg, 0.109 mmol) in dichloromethane (3 ml) under an argon atmosphere, and 1 hour at room temperature. Stir. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography (20 cm × 20 cm × 0.5 mm × 2 sheets; hexane-ethyl acetate (1: 2)) to give thiazoline 8 (17.4 mg, 55%) as a yellow solid Obtained.

Thiazoline 8
¹ H NMR (270 MHz, CD ₃ OD)
δ3.63 (2H, dd, J = 3.1, 8.9Hz), 3.8 1 (3H, s), 5.27 (1H, t, J = 8.9Hz), 7.07 to 7.13 (2H, complex), 7.33 (1H, d , J = 16.1Hz), 7.55-7.83 (4H, complex).

Synthesis of analog 9

  Thiazoline 8 (6.3 mg, 0.0201 mmol) was dissolved in a mixed solvent of ethanol (2 mL) and 10 mM aqueous ammonium hydrogen carbonate solution (8 mL), and a small amount of porcine liver esterase was added under an argon atmosphere. After stirring at 36 ° C. for 17 hours, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give analog 9 (7.6 mg, quant.) As a yellow solid.

Analog 9
¹ H NMR (270 MHz, CD ₃ OD)
δ 3.61 (2H, dd, J = 3.1, 8.9Hz), 5.09 (1H, t, J = 8.9Hz), 7.06-7.17 (2H, complex), 7.30 (1H, dd, J = 16.1Hz), 7.65- 7.87 (4H, complex).

Synthesis of analog 10

  4-Cyanophenol (109 mg, 0.916 mmol) and D-cysteine hydrochloride monohydrate (527 mg, 3.00 mmol) are dissolved in ethanol (5 ml), and 1 M aqueous sodium hydroxide solution (5 ml) is added under an argon atmosphere. And stirred at 80 ° C. for 19 hours. The reaction mixture was allowed to cool and then neutralized using a cation exchange resin. Water (50 ml) was added to the solution obtained by filtering the resin and extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give analog 10 (190 mg, 93%) as a yellow solid.

Analog 10
mp 200-207 ℃
IR (film) 2680 (br.), 1610, 1580, 1510cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ 3.70 (1H, d, J = 8.6Hz), 3.78 (1H, d, J = 8.6Hz), 5.23 (1H, t, J = 8.6Hz), 6.79 (2H, d, J = 8.9Hz), 7.66 (2H, d, J = 8.9Hz),
¹³ C NMR (67.8MHz, CDCl ₃ )
δ35.95 (t), 77.97 (d), 116.5 (d) x 2, 124.5 (s), 131.8 (d) x 2, 163.0 (s), 173.9 (s), 174.6 (s)
MS (EI) m / z 223 (M ⁺ ,), 178 (100%), 137 (13%), 121 (19%).

Synthesis of acetyl 11

  Acetic anhydride (2.0 ml, 21 mmol) and 4-dimethylaminopyridine (1.13 g, 9.93 mmol) were added to a dichloromethane solution (40 ml) of p-hydroxycinnamic acid (502.2 mg, 3.06 mmol), and the mixture was stirred at room temperature for 4 hours. . Water (150 ml) was added to the reaction mixture and extracted with chloroform (3 × 150 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 90 g; chloroform: methanol 50: 1) and preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 3; chloroform-methanol (10: 1)}. Then, acetyl derivative 11 (549 mg, 87%) was obtained as a yellow solid.

Acetyl 11
mp 182-183 ℃
IR (film) 3050, 1740, 1680, 1630cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ2.32 (3H, s), 6.41 (1H, d, J = 16Hz), 7.15 (2H, d, J = 8.6Hz), 7.57 (2H, d, J = 8.6Hz), 7.76 (1H, d, J = 16Hz)
¹ H NMR (270 MHz, CD ₃ OD)
δ2.28 (3H, s), 6.46 (1H, d, J = 16Hz), 7.15 (2H, d, J = 8.6Hz), 7.62-1.65 (3H, complex)
¹ H NMR (270 MHz, ACETN)
δ2.28 (3H, s), 6.52 (1H, d, J = 16Hz), 7.21 (2H, d, J = 8.4Hz), 7.66-7.76 (3H, complex)
¹³ C NMR (67.8MHz, CDCl ₃ )
δ20.95 (q), 121.0 (d), 123.4 (d) × 2, 123.2 (d) × 2, 133.9 (s), 144.2 (d), 153.6 (s), 170.9 (s), 171.2 (s)
MS (EI) m / z 206 (M ⁺ , 14), 164 (100), 147 (20), 119 (12), 92 (14).

Synthesis of amide 12

  Acetyl 11 (92.1 mg, 0.482 mmol), 1-ethyl-3- (3-dimethylaminopropyl) hydrochloride in N, N-dimethylformamide solution (5 ml) in methyl ester 6 (184 mg, 0.485 mmol) under argon atmosphere Carbodiimide (196 mg, 1.02 mmol) and 4-dimethylaminopyridine (124 mg, 1.02 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Water (100 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 100 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 181 g; hexane-ethyl acetate (1: 1)} to obtain amide 12 (214 mg, 80%) as a yellow oil.

Amide 12
IR (neat) 3280, 1760, 1740, 1660, 1630cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ2.32 (3H, s), 2.70 (1H, dd, J = 4.6, 12Hz), 2.78 (1H, dd, J = 5.4, 12Hz), 3.72 (3H, s), 4.76 (1H, dd, J = 4.6, 5.4Hz), 7.10-7.31 (9H, complex), 7.36-7.41 (6H, complex), 7.52 (2H, d, J = 8.4Hz), 7.57 (1H, d, J = 15Hz)
¹³ C NMR (67.8MHz, CD ₃ OD)
δ 21.17 (q), 33.93 (t), 51.19 (d), 52.76 (q), 66.99 (s), 120.0 (d), 122.1 (d) × 2, 126.9 (d) × 3, 128.0 (d) × 6, 129.0 (d) x 2, 129.5 (d) x 6, 132.4 (s), 140.8 (d), 144.3 (s), 151.8 (s), 165.1 (s), 169.3 (s), 170.9 (s) .

Synthesis of thiazoline 13

  Triphenylphosphine oxide (33.2 mg, 0.119 mmol) and trifluoromethanesulfonic anhydride (50 μl, 0.297 mmol) were added to a dichloromethane solution (11 ml) of amide 12 (31.3 mg, 0.0553 mmol) under an argon atmosphere. Stir for hours. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 2 sheets; hexane-ethyl acetate (1: 2)} to obtain thiazoline 13 (12.6 mg, 71%) as a yellow solid Obtained.

Thiazoline 13
mp 118-121 ℃
IR (film) 1760, 1720cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ2.31 (3H, s), 3.56 (1H, dd, J = 9.2, 11Hz), 3.70 (1H, dd, J = 9.2, 11Hz), 3.85 (3H, s), 5.22 (1H, t, J = 9.2Hz), 7.03 (1H, d, J = 16Hz) 7.13 (2H, d, J = 8.6Hz), 7.15 (1H, d, J = 16Hz), 7.50 (2H, d, J = 8.6Hz)
¹³ C NMR (67.8MHz, CD ₃ OD)
δ 21.15 (q), 34.64 (t), 52.89 (q), 77.96 (d), 122.2 (d) × 2, 122.4 (d), 128.7 (d) × 2, 132.8 (s), 141.1 (d), 151.7 (s) x 2, 169.2 (s), 132.4 (s), 170.0 (s), 171.2 (s)
MS (EI) m / z 305 (M ⁺ , 44), 263 (88), 205 (100), 177 (69), 163 (15).

Synthesis of analog 14

  Thiazoline 13 (14.9 mg, 0.0488 mmol) was dissolved in a mixed solvent of ethanol (2 ml) and 10 mM aqueous ammonium hydrogen carbonate solution (8 ml), and a small amount of porcine liver esterase was added under an argon atmosphere. After stirring at 36 ° C. for 17 hours, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give analog 14 14.7 mg, quant.) As a yellow solid.

Analog 14
mp 138-140 ℃
IR (film) 3150, 1630, 1570cm ^-1
1 H NMR (270 MHz, CD ₃ OD)
δ3.54 (1H, dd, J = 9.2, 11Hz), 3.59 (1H, dd, J = 9.2, 11Hz), 5.02 (1H, t, J = 9.2Hz), 6.79 (1H, d, J = 8.4Hz ), 6.92 (1H, d, J = 16Hz), 7.12 (1H, d, J = 16Hz), 7.43 (2H, d, J = 8.4Hz)
¹³ C NMR (67.8MHz, CD ₃ OD)
δ 36.54 (t), 81.19 (d), 116.9 (d) × 2, 119.7 (d), 128.0 (s), 130.5 (d) × 2, 132.8 (s), 143.7 (d), 160.7 (s), 172.0 (s), 177.5 (s).

Example 3: Synthesis of OH-benzene-diene type silyl compound 15

  To a solution (4 ml) of 4-hydroxybenzaldehyde (409 mg, 3.35 mmol) in t-butyldimethylsilyl chloride (834 mg, 5.53 mmol) and 4-dimethylaminopyridine (734 mg, 5.99 mmol) were added and stirred for 2 hours. Water (150 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (150 ml) and ethyl acetate (2 × 150 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 33 g; hexane-chloroform (1: 2)} to obtain silyl compound 15 (773 mg, 98%) as a yellow oil.

Cyril body 15
IR (neat) 1699cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ0.01 (6H, s), 0.76 (9H, s), 6.70 (2H, dd, J = 6.8, 16Hz), 7.55 (2H, dd, J = 6.8, 16Hz)
MS (EI) m / z 236 (M ⁺ , 43), 179 (100).

Synthesis of ester 16

  The silyl compound 15 (773 mg, 3.28 mmol) was dissolved in toluene (5 ml), carbethoxymethylenetriphenylphosphorane (1.24 g, 3.55 mmol) was added, and the mixture was heated to reflux for 3.5 hours. The reaction mixture was allowed to cool, water (50 ml) was added, and the mixture was extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 92 g; hexane: chloroform (1: 2)} to obtain ester 16 (895 mg, 89%) as a yellow oil.

Ethyl ester 16
IR (KBr tablet method) 1716cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ0.01 (6H, s), 0.77 (9H, s), 1.11 (3H, t, J = 7.3Hz), 4.04 (2H, q, J = 7.3Hz), 6.08 (1H, d, J = 16Hz) , 6.62 (2H, dd, J = 1.9, 6.5Hz), 7.20 (2H, dd, J = 1.9, 6.5Hz), 7.42 (1H, q, J = 16Hz)
MS (EI) m / z 306 (M ^+. , 53), 261 (9), 249 (100), 203 (22).

Synthesis of alcohol 17

  Ethyl ester 16 (197 mg, 0.643 mmol) was dissolved in toluene (2 ml), a toluene solution of diisobutylaluminum hydride (3.0 ml, 3.0 mmol) was added, and the mixture was stirred at room temperature for 3 hours. Water (100 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 10 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 1.75 mm 1 sheet; hexane-ethyl acetate (2: 1)} to obtain alcohol 17 (141 mg, 83%) as a colorless oil. .

Alcohol 17
IR (neat) 3388cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ0.01 (6H, s), 0.98 (9H, s), 4.30 (2H, t, J = 5.9Hz), 6.25 (2H, dt, J = 5.9, 16Hz), 6.56 (2H, d, J = 8.6 Hz), 6.80 (2H, d, J = 8.6Hz), 7.28 (2H, d, J = 8.6Hz)
¹ H NMR (270 MHz, CD ₃ OD)
δ0.01 (6H, s), 0.80 (9H, s), 4.01 (2H, d, J = 5.9Hz), 6.03 (2H, dt, J = 5.9, 16Hz), 6.35 (2H, d, J = 16Hz) ), 6.60 (2H, dd, J = 1.9, 8.6Hz), 7.11 (2H, dd, J = 1.9, 8.6Hz)
MS (EI) m / z 264 (M ⁺ , 54), 207 (100), 189 (20), 115 (20), 75 (22).

Synthesis of aldehyde 18

  Alcohol 17 (62.8 mg, 0.239 mmol) was dissolved in a dichloromethane solution (1.5 ml), Dess Martin reagent (205 mg, 0.484 mmol) was added, and the mixture was stirred at room temperature for 1.5 hours. An aqueous sodium hydrogen carbonate solution (25 ml) and an aqueous sodium thiosulfate solution (25 ml) were added to the reaction mixture, followed by extraction with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 1; hexane-ethyl acetate (2: 1)} to obtain aldehyde 18 (141 mg, 76%) as a yellow oil. .

Aldehyde 18
IR (KBr tablet method) 1675cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ0.01 (6H, s), 0.77 (9H, s), 6.37 (1H, dd, J = 7.8, 16Hz), 6.56 (2H, d, J = 8.6Hz), 6.66 (2H, d, J = 8.6 Hz), 7.20 (1H, d, J = 16Hz), 7.25 (2H, d, J = 8.6Hz), 9.43 (1H, d, J = 7.8Hz),
MS (EI) m / z 262 (M ⁺ , 47), 207 (25), 206 (100).

Synthesis of ester 19

  Aldehyde 18 (47.6 mg, 0.181 mmol) was dissolved in toluene (1 ml), carbethoxymethylenetriphenylphosphorane (132 mg, 0.380 mmol) was added, and the mixture was heated to reflux at room temperature for 4 hours. The reaction mixture was allowed to cool, water (50 ml) was added, and the mixture was extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 1; hexane-ethyl acetate (2: 1)} to give ethyl ester 19 (45.4 mg, 76%) as a yellow oil Obtained.

Ethyl ester 19
IR (neat) 1705cm ^-1
1 H NMR (270 MHz, CDCl ₃ )
δ0.01 (6H, s), 0.78 (9H, s), 1.11 (3H, t, J = 7.3Hz), 4.04 (2H, q, J = 7.3Hz), 5.74 (1H, d, J = 7.8, 15Hz), 6.55-6.68 (4H, complex), 7.15 (2H, dd, J = 2.2Hz), 7.25 (1H, d, J = 15Hz),
MS (EI) m / z 332 (M ⁺ , 41), 275 (22), 218 (100), 173 (28), 145 (92).

Synthesis of carboxyl 20

  Ethyl ester 19 (9.7 mg, 0.0292 mmol) was dissolved in isopropyl alcohol solution (1 ml), 1M aqueous sodium hydroxide solution (1 ml, 1 mmol) was added, and the mixture was stirred at 50 ° C. for 20 hours. The reaction mixture was allowed to cool and then neutralized with cation exchange resin IR-120B NA. The resin was filtered off, and the resulting solution was concentrated under reduced pressure to give carboxyl 20 (10.3 mg, quant.) As a yellow solid.

Carboxyl compound 20
IR (KBr tablet method) 3311, 1670cm ^-1
1 H NMR (270 MHz, CD ₃ OD)
δ5.74 (1H, d, J = 7.8, 15Hz), 6.55-6.68 (4H, complex), 7.38 (2H, d, J = 8.9Hz), 7.45 (1H, d, J = 15Hz)
MS (EI) m / z 190 (M ⁺ , 9), 183 (100), 149 (43), 105 (58).

Synthesis of amide 21

  Ester 6 (32.3 mg, 0.170 mmol) in N, N-dimethylformamide solution (1 ml) under argon atmosphere, carboxyl 20 (32.3 mg, 0.170 mmol), 1-ethyl-3- (3-dimethylaminopropyl hydrochloride) ) Carbodiimide (110 mg, 0.573 mmol) and 4-dimethylaminopyridine (64.9 mg, 0.532 mmol) were added, and the mixture was stirred at room temperature for 5 hours. Water (150 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 100 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm × 1; chloroform-methanol (10: 1)} to obtain amide 21 (44.5 mg, 48%) as a yellow oil. .

Amide 21
IR (neat) 3290, 1739, 1652cm ^-1
1 H NMR (270 MHz, CD ₃ OD)
δ5.91 (1H, d, 15Hz), 6.76-6.92 (4H, complex), 1.11 (3H, t, J = 7.3Hz), 4.04 (2H, q, J = 7.3Hz), 5.74 (1H, d, J = 7.8, 15Hz), 6.55-6.68 (4H, complex), 7.38 (2H, d, J = 8.9Hz), 7.45 (1H, d, J = 15Hz).

Synthesis of thiazoline 22

  Triphenylphosphine oxide (45.7 mg, 0.164 mmol) and trifluoromethanesulfonic anhydride (0.4 ml, 2.38 mmol) were added to a dichloromethane solution (1 ml) of amide compound 21 (44.5 mg, 0.0811 mmol) in an argon atmosphere at room temperature. For 40 minutes. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (50 ml) and ethyl acetate (2 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm 2 sheets; hexane-ethyl acetate (1: 2)} to obtain thiazoline 22 (4.6 mg, 20%) as a light yellow solid. Obtained.

Thiazoline 22
¹ H NMR (270 MHz, CDCl ₃ )
δ2.71 (2H, d, 8.9Hz), 3.66 (3H, s), 4.72 (1H, t, J = 8.9Hz), 5.85 (2H, d, J = 15Hz), 6.21-7.46 (22H, d, complex).

Synthesis of analog 23

  Thiazoline 22 (4.6 mg, 0.0159 mmol) was dissolved in a mixed solvent of ethanol (2 ml) and 10 mM aqueous ammonium bicarbonate (8 ml), and a small amount of porcine liver esterase was added under an argon atmosphere. After stirring at 36 ° C. for 18 hours, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give analog 23 (9.5 mg, quant.) As a yellow solid.

Analog 23
IR (KBr tablet method) 3396, 1596cm ^-1
1 H NMR (270 MHz, CD ₃ OD)
δ4.25 (2H, d, 7.3Hz), 5.21 (1H, t, J = 7.3Hz), 6.52 (2H, d, J = 15Hz), 6.75-7.56 (7H, complex), 6.76 (2H, d, J = 8.9Hz), 7.37 (2H, d, J = 8.9Hz)
MS (ESI) [M + H] ⁺ ; m / z 276.0694.

Example 5: Synthesis of dimethylamino-benzene type analog 24

  4-Dimethylaminobenzonitrile (103 mg, 0.706 mmol) and D-cysteine hydrochloride monohydrate (371 mg, 2.12 mmol) are dissolved in ethanol (4 ml), and 1M aqueous sodium hydroxide solution (5 ml) is added under an argon atmosphere. The mixture was further stirred at 80 ° C. for 5 hours. The reaction mixture was acidified with 1M hydrochloric acid (5 ml), and concentrated under reduced pressure. The resulting solid was filtered and washed with distilled water to give analog 24 (50.9 mg, quant.) As a yellow solid.

Analog 24
¹ H NMR (270 MHz, CDCl ₃ )
δ3.01 (6H, s), 3. (1H, dd, J = 9.2, 11Hz), 3. (1H, dd, J = 9.2, 11Hz), 5.00 (1H, t, J = 9.2Hz), 6.71 (2H, dd, J = 2.4, 7.0Hz), 7.71 (2H, dd, J = 2.4, 7.0Hz).

Example 6: Synthesis of dimethylamino-benzene-monoene amide 25

  Methyl ester 6 (184 mg, 0.485 mmol) in N, N-dimethylformamide solution (5 ml) under argon atmosphere, p-dimethylaminocinnamic acid (92.1 mg, 0.482 mmol), 1-ethyl-3- (3- Dimethylaminopropyl) carbodiimide (196 mg, 1.02 mmol) and 4-dimethylaminopyridine (124 mg, 1.02 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Water (100 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 100 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 181 g; hexane-ethyl acetate (1: 1)} to obtain amide 25 (214 mg, 80%) as a yellow oil.

Amide 25
¹ H NMR (270 MHz, CDCl ₃ )
δ2.72 (2H, t, J = 5.1Hz), 2.99 (6H, s), 3,71 (3H, s), 4.78 (1H, dd, J = 5.1, 7.8Hz), 6.05 (1H, d, J = 7.8Hz), 6.15 (1H, d, J = 15Hz), 6.68 (1H, d, J = 8.6Hz), 7.10-7.31 (9H, complex), 7.35-7.41 (6H, complex), 7.53 (1H , d, J = 15Hz).

Synthesis of thiazoline 26

  Triphenylphosphine oxide (124 mg, 0.446 mmol) and trifluoromethanesulfonic anhydride (360 μl, 2.14 mmol) were added to a dichloromethane solution (10 ml) of amide 25 (118 mg, 0.214 mmol) under an argon atmosphere, and the mixture was stirred at room temperature for 40 minutes. did. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (50 ml) and ethyl acetate (2 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography {silica gel 42 g; hexane-ethyl acetate (1: 2)} to obtain thiazoline 26 (44.2 mg, 71%) as a yellow solid.

Thiazoline 26
¹ H NMR (270 MHz, CDCl ₃ )
δ3.02 (6H, s), 3.57 (1H, d, J = 8.6Hz), 3.59 (1H, d, J = 8.6Hz), 3,84 (3H, s), 5.19 (1H, t, J = 8.6Hz), 6.67 (1H, d, J = 8.9Hz), 6.92 (1H, d, J = 16Hz), 7.08 (1H, d, J = 16Hz), 7.39 (2H, d, J = 8.9Hz).

Synthesis of analog 27

  Thiazoline 26 (16.3 mg, 0.0591 mmol) was dissolved in a mixed solvent of ethanol (2 ml) and 10 mM aqueous ammonium hydrogen carbonate solution (8 ml), and a small amount of porcine liver esterase was added under an argon atmosphere. After stirring at 36 ° C. for 19 hours, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give analog 27 (15.2 mg, quant.) As an orange solid.

Analog 27
¹ H NMR (270 MHz, CDCl ₃ )
δ3.02 (6H, s), 3.57 (1H, d, J = 8.6Hz), 3.59 (1H, d, J = 8.6Hz), 3,80 (3H, s), 5.19 (1H, t, J = 8.6Hz), 6.73 (1H, d, J = 8.9Hz), 6.87 (1H, d, J = 16Hz), 7.23 (1H, d, J = 16Hz), 7.45 (2H, d, J = 8.9Hz)
MS (ESI) [M + H] ⁺ ; m / z 277.1011.

Example 7: Synthesis of dimethylamino-benzene-diene type ethyl ester 28

  4-Dimethylaminocinnamic aldehyde (104 mg, 0.592 mmol) was dissolved in toluene (9 ml), carbethoxymethylenetriphenylphosphorane (621.6 mg, 1.78 mmol) was added, and the mixture was heated to reflux for 4.5 hours. The reaction mixture was allowed to cool, water (50 ml) was added, and the mixture was extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography {silica gel 192 g; hexane-ethyl acetate (3: 2)} to obtain ethyl ester 28 (144 mg, 99%) as a yellow solid.

Ethyl ester 28
¹ H NMR (270 MHz, CD ₃ Cl ₃ )
δ1.57 (3H, s), 3.00 (6H, s), 4.21 (2H, q), 5.87 (1H, d, J = 15Hz), 6.67 (2H, d, J = 8.9Hz), 6.83 (1H, d, J = 15Hz), 7.37 (2H, d, J = 8.9Hz), 7.42 (1H, d, J = 15Hz), 7.46 (1H, d, J = 15Hz)
MS (EI) m / z 245 (M ⁺ ., 100%).

Synthesis of carboxyl 29

  Ethyl ester 28 (235 mg, 1.08 mmol) was dissolved in isopropyl alcohol (7 ml), and 1M aqueous sodium hydroxide solution (4 ml, 4 mmol) was added. After stirring at room temperature for 3 days, the mixture was neutralized with 1M hydrochloric acid. Water (50 ml) was added thereto, and the mixture was extracted with ethyl acetate (3 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain carboxyl compound 29 (137.1 mg, 58%) as a yellow solid.

Carboxyl 29
¹ H NMR (270 MHz, CD ₃ OD)
δ2.98 (6H, s), 5.86 (1H, d, J = 15Hz), 6.70-6.90 (3H, complex), 6.72 (2H, d, J = 8.9Hz), 7.37-7.45 (4H, complex), 7.38 (2H, d, J = 8.9Hz),
MS (EI) m / z 217 (M ⁺ ., 100%).

Synthesis of amide 30

  Methyl ester 6 (131 mg, 0.347 mmol) in N, N-dimethylformamide solution (6 ml) under argon atmosphere, carboxyl 29 (88.6 mg, 0.430 mmol), 1-ethyl-3- (3-dimethylaminopropyl) hydrochloride Carbodiimide (209 mg, 1.09 mmol) and 4-dimethylaminopyridine (138 mg, 1.12 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Water (150 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 × 150 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 166 g; hexane-ethyl acetate (1: 1)} to obtain amide 30 (96.3 mg, 40%) as a yellow oil.

Amide 30
¹ H NMR (270 MHz, CD ₃ OD)
δ 2.69 (1H, dd, J = 4.8, 13.1Hz), 2.85 (1H, dd, J = 8.8, 13.1Hz), 3.66 (3H, s), 4.43 (1H, dd, J = 4.8, 8.8Hz) , 6.84 (1H, dd, J = 2.0, 8.6Hz), 6.97 (1H, br.s), 7.20-7.31 (9H, complex), 7.38-7.41 (7H, complex), 7.51 (1H, d, J = 8.6Hz)
¹³ C NMR (67.8MHz, CD ₃ OD)
δ34.32 (t), 53.03 (q), 53.18 (d), 68.31 (s), 98.70 (d), 112.49 (d), 114.95 (d), 121.05 (s), 124.13 (d), 127.95 (d ), 129.01 (d), 130.72 (d), 145.87 (s), 148.01 (s), 158.03 (s), 159.63 (s), 161.04 (s), 172.02 (s).

Synthesis of thiazoline 31

  Triphenylphosphine oxide (44.9 mg, 0.161 mmol) and trifluoromethanesulfonic anhydride (17 μl, 0.101 mmol) were added to a dichloromethane solution (5 ml) of amide 30 (43.3 mg, 0.0751 mmol) under an argon atmosphere, and 80 ° C. at room temperature. Stir for minutes. Water (50 ml) was added to the reaction mixture, and the mixture was extracted with chloroform (50 ml) and ethyl acetate (2 × 50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by preparative thin layer chromatography {20 cm × 20 cm × 0.5 mm 3 sheets; hexane-ethyl acetate (1: 1)} to obtain thiazoline 31 (17.6 mg, 74%) as a light yellow solid. Obtained.

Thiazoline 31
¹ H NMR (270 MHz, CDCl ₃ )
δ3.00 (6H, s), 3.54 (1H, dd, J = 8.9,11Hz), 3.57 (1H, dd, J = 8.9,11Hz), 5.17 (1H, t, J = 8.9Hz), 6.54 (1H , d, J = 15 Hz), 6.65-6.80 (4H, complex), 6.94 (1H, dd, J = 8.9, 15 Hz) 7.36 (2H, d, J = 8.9 Hz).

Synthesis of analog 32

  Thiazoline 31 (12.7 mg, 0.0402 mmol) was dissolved in a mixed solvent of ethanol (2 ml) and 10 mM aqueous ammonium hydrogen carbonate solution (6 ml), and a small amount of porcine liver esterase was added under an argon atmosphere. After stirring at 36 ° C. for 25 hours, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give analog 32 (10.2 mg, quant.) As a pale yellow solid.

Analog 32
¹ H NMR (270 MHz, CD ₃ OD)
δ2.98 (6H, s), 3.54 (1H, d, J = 8.9Hz), 3.57 (1H, d, J = 8.9Hz), 5.19 (1H, t, J = 8.9Hz), 6.47 (1H, d , J = 15Hz), 6.70-7.06 (5H, complex), 7.38 (2H, d, J = 8.9Hz)

Example 8-1: Deprotection of methyl (synthesis of phenol 13)

  Pyridinium chloride (30.6 g, 265 mmol) was added to commercially available 2-cyano-6-methoxybenzothiazole (651.7 mg, 3.43 mmol), heated to 20 ° C. under an argon atmosphere, and pyridinium chloride was melted and stirred for 30 minutes. . The reaction mixture was allowed to cool, 1 M hydrochloric acid (80 ml) was added, and the mixture was extracted with ethyl acetate (4 × 60 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography {silica gel 85 g; chloroform-methanol (10: 1)} to obtain phenol 13 (448.8 mg, 74%) as a yellow solid. The raw material (213.4 g, 1.12 mmol) was recovered.

Phenol body 13
mp 155-170 ° C decomp.
IR (film) 3178, 2225 cm ^-1
1 H NMR (270 MHz, CD ₃ OD): δ 7.17 (1H, dd, J = 2.6, 8.9Hz), 7.40 (1H, d, J = 2.6Hz), 7.99 (1H, d, J = 8.9Hz)
¹³ C NMR (67.8 MHz, CD ₃ OD): δ 107.00 (d), 114.29 (s), 119.61 (d), 126.58 (d), 133.91 (s), 139.01 (s), 147.29 (s), 160.32 ( s)
MS (EI) m / z 176 (M ^+. , 100), 124 (5).

Example 8-2: Synthesis of firefly luciferin

  Phenol compound 13 (20.0 mg, 0.114 mmol) and D-cysteine hydrochloride monohydrate (19.7 mg, 0.125 mmol) are dissolved in methanol: distilled water (2: 1) (3.0 ml), and carbonated under an argon atmosphere. Potassium (17.0 mg, 0.123 mmol) was added and stirred at room temperature for 30 minutes. The reaction mixture was acidified with 0.2 ml of 1 M hydrochloric acid, and concentrated under reduced pressure. The resulting solid was filtered and washed with distilled water to give firefly luciferin (1) (23.5 mg, 74%) as a yellow solid.

Firefly luciferin (1)
¹ H NMR (270 MHz, DMSO-d ₆ ): δ 3.66 (1H, dd, J = 8.2, 11.2Hz), 3.67 (1H, dd, J = 9.9, 11.2Hz), 5.40 (1H, dd, J = 8.2, 9.9Hz), 7.06 (1H, dd, J = 2.6, 8.9Hz), 7.51 (1H, d, J = 2.6Hz), 7.96 (1H, d, J = 8.9Hz), 10.24 (1H, br. s, OH)
¹³ C NMR (67.8 MHz, DMSO-d ₆ ): δ 34.5 (t), 78.0 (d), 106.7 (d), 117.0 (d), 124.8 (d), 137.1 (s), 146.1 (s), 157.3 (S), 159.8 (s), 164.3 (s), 171.1 (s).

Example 9: Measurement of bioluminescence spectrum
1) Measuring equipment High-performance liquid chromatography (HPLC)
An Agilent 1100 series HPLC manufactured by Agilent Technologies was used. The breakdown of the equipment is degasser, quaternary pump, manual injector, column compartment, diode array detector, fluorescence detector, and ChemStation (PC software). The column used was CHIRALCEL OD-RH (inner diameter 0.46 cm, length 15 cm) manufactured by Daicel Chemical Industries, Ltd.

pH measurement The measurement was performed using an F-23 type glass electrode type hydrogen ion concentration indicator manufactured by Horiba.

Photon quantity measurement
Measurement was performed using Luminescencer-PSN AB-2200 manufactured by ATTO Corporation.

Emission spectrum measurement
The measurement was performed using a weak emission fluorescence spectrum apparatus AB-1850 manufactured by ATTO Corporation. All measured spectra are spectra corrected for the characteristics of the detector.

2) Reagents Ultrapure water was collected from Milli-RX12α manufactured by Millipore. For methanol and t-butanol, special grade solvents manufactured by Kanto Chemical Co., Ltd. were used.

  As the luciferase (derived from the North American firefly Photinus pyralis), a recombinant type manufactured by Sigma or Promega was used.

  ATP-Mg manufactured by Sigma was used.

  The phosphate buffer solution is prepared by dissolving dipotassium hydrogen phosphate hydrate (special grade) and potassium dihydrogen phosphate hydrate (special grade) manufactured by Wako Pure Chemical Industries, Ltd. in ultrapure water and adjusting the pH. Used.

  Potassium t-butoxide used was made by Tokyo Chemical Industry Co., Ltd.

  For distilled water and acetonitrile, a solvent for high performance liquid chromatography manufactured by Kanto Chemical Co., Inc. was used.

  Trifluoroacetic acid (made by Wako Pure Chemical Industries, Ltd.) (special grade) was used.

3) Sample preparation Substrate solution The substrate was weighed and diluted with an electronic balance. As the solvent, phosphate buffer (50 mM, pH 6.0) was used for bioluminescence measurement, and t-butanol was used for chemiluminescence measurement.

Enzyme solution The luciferase was diluted with Tris-HCl buffer solution (50 mM, pH 8.0) to 1 μg / μl, and divided into small portions. This was used as a stock solution, and the necessary amount was diluted each time. The stock solution was stored in a -80 ° C freezer.

ATP-Mg solution
ATP-Mg was diluted with ultrapure water.

Bioluminescence spectrum
In a 200 μL polystyrene tube, mix potassium phosphate buffer (0.5 M, pH 8.0, 20 μl), substrate solution (2.5 mM, 20 μl), enzyme solution (20 μl), then ATP-Mg solution (10 mM, 40 μl). The emission spectrum was measured. The concentration of the enzyme solution used was 17 μM. However, firefly luciferin (1) used 1.7 μM, and phenol-type luciferin used 170 μM. The exposure time for emission spectrum measurement was 60 seconds. However, firefly luciferin was performed in 5 seconds.

Experimental Results Using the above procedure, the emission wavelength of the compound shown in FIG. 1 was measured. The compounds shown in FIG. 1 had the emission wavelengths described under each compound.

  From the structure of the luciferin analog in FIG. 1 and its emission wavelength, it was found that in the structure of the luciferin analog, the emission wavelength shifted to the long wavelength side by about 100 nm each time one double bond was extended. In addition, in the structure of the luciferin analog, it was found that the emission wavelength is shifted by about 20 to 30 nm to the longer wavelength side by converting the double bond portion into a benzene ring. Further, it was found that in the structure of the luciferin analog, by changing the dialkylamino group to a hydroxyl group, the emission wavelength is shifted to the short wavelength side by about 20 to 30 nm. As a result, an index for changing a practical emission wavelength could be established. By designing a luciferin derivative based on this index, a compound having a desired emission wavelength can be produced.

  In addition, based on the emission wavelength shift law shown in FIG. 2, a compound group having an emission wavelength over the entire visible region can be produced, such as the luciferin analog shown in FIG.

Claims (4)

Luciferin analogs of general formula III:

Where
R ₁ , R ₂ and R ₃ are each independently H or C _1-4 alkyl;
X and Y are each independently C, N, S or O;
n is 2 . The compound according to claim 1, wherein the R ₁ R ₂ N- group is an OH- group and R ₃ is H. A luminescent substrate comprising the luciferin analog according to claim 1 or 2 . A luminescence detection kit comprising the luciferin analog according to claim 1 or 2 .